Compare IOVA & DV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | DV |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2008 | 2021 |
| Metric | IOVA | DV |
|---|---|---|
| Price | $4.91 | $10.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 15 |
| Target Price | $9.00 | ★ $16.37 |
| AVG Volume (30 Days) | ★ 16.3M | 2.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.84 | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $748,291,000.00 |
| Revenue This Year | $47.74 | $12.68 |
| Revenue Next Year | $40.31 | $9.75 |
| P/E Ratio | ★ N/A | $264.00 |
| Revenue Growth | N/A | ★ 13.92 |
| 52 Week Low | $1.76 | $7.61 |
| 52 Week High | $5.64 | $16.82 |
| Indicator | IOVA | DV |
|---|---|---|
| Relative Strength Index (RSI) | 60.02 | 50.91 |
| Support Level | $3.77 | $10.76 |
| Resistance Level | $5.63 | $11.60 |
| Average True Range (ATR) | 0.40 | 0.43 |
| MACD | 0.05 | -0.14 |
| Stochastic Oscillator | 68.35 | 43.64 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
DoubleVerify Holdings Inc is a media effectiveness platform that leverages artificial intelligence (AI) to drive superior outcomes for international brands by creating transparent ad transactions. Its solutions provide unbiased data analytics to improve the effectiveness, quality and return on advertising investments. DV Authentic Ad is its proprietary metric measuring whether an ad was delivered in a brand suitable environment, fully viewable, by a real person and in geography, while DV Pinnacle delivers these metrics in real time. The Company's solutions are integrated across programmatic platforms, social media channels and digital publishers, and are accredited by the Media Rating Council for digital ad measurement. It operates in the United States and international markets.